MRI biomarker assessment of neuromuscular disease progression: A prospective observational cohort study

The Lancet Neurology

Volumn 15, Issue 1, 2016, Pages 65-77

  Morrow, Jasper M ^a   Sinclair, Christopher D J ^a   Fischmann, Arne ^a,c   Machado, Pedro M ^a   Reilly, Mary M ^a   Yousry, Tarek A ^a,b   Thornton, John S ^a,b   Hanna, Michael G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHARCOT MARIE TOOTH DISEASE 1A; CHROMOSOME 17P11.2 DUPLICATION; CHROMOSOME DUPLICATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FAST MUSCLE; FEMALE; FOLLOW UP; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INCLUSION BODY MYOSITIS; LIPID STORAGE; LOWER LIMB; MALE; MIDDLE AGED; NEUROIMAGING; NEUROMUSCULAR DISEASE; NEUROPATHOLOGY; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAXATION TIME; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; CHARCOT-MARIE-TOOTH DISEASE; DISEASE COURSE; LONGITUDINAL STUDY; NEUROMUSCULAR DISEASES; TRENDS;

ADULT; AGED; BIOMARKERS; CHARCOT-MARIE-TOOTH DISEASE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROMUSCULAR DISEASES; PROSPECTIVE STUDIES;

EID: 84949519166     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00242-2     Document Type: Article

References (46)

1. Braathen GJ Genetic epidemiology of Charcot-Marie-Tooth disease. Acta Neurol Scand Suppl 2012, 193:iv-22.
2. Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009, 132:3175-3186.
3. Arechavala-Gomeza V, Anthony K, Morgan J, Muntoni F Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. Curr Gene Ther 2012, 12:152-160.
4. Verhamme C, van Schaik IN, Koelman JHTM, de Haan RJ, de Visser M The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009, 132:3252-3262.
5. Liang MH, Fossel AH, Larson MG Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990, 28:632-642.
6. Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011, 10:320-328.
7. Reilly MM, Shy ME, Muntoni F, Pareyson D 168th ENMC international workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord 2010, 20:839-846.
8. Glover GH, Schneider E Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn Reson Med 1991, 18:371-383.
9. Hiba B, Richard N, Hébert LJ, et al. Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI. J Magn Reson Imaging 2012, 35:678-685.
10. Gaeta M, Scribano E, Mileto A, et al. Muscle fat fraction in neuromuscular disorders: dual-echo dual-flip-angle spoiled gradient-recalled MR imaging technique for quantification-a feasibility study. Radiology 2011, 259:487-494.
11. Gloor M, Fasler S, Fischmann A, et al. Quantification of fat infiltration in oculopharyngeal muscular dystrophy: comparison of three MR imaging methods. J Magn Reson Imaging 2011, 33:203-210.
12. Wren TAL, Bluml S, Tseng-Ong L, Gilsanz V Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. Am J Roentgenol 2008, 190:W8-12.
13. Willis TA, Hollingsworth KG, Coombs A, et al. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 2013, 8:e70993.
14. Sinclair CDJ, Morrow JM, Miranda MA, et al. Skeletal muscle MRI magnetisation transfer ratio reflects clinical severity in peripheral neuropathies. J Neurol Neurosurg Psychiatry 2012, 83:29-32.
15. Willcocks RJ, Arpan IA, Forbes SC, et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 2014, 24:393-401.
16. Morrow JM, Sinclair CDJ, Fischmann A, et al. Reproducibility, and age, body-weight and gender dependency of candidate skeletal muscle MRI outcome measures in healthy volunteers. Eur Radiol 2014, 24:1610-1620.
17. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010, 20:142-147.
18. Machado PM, Ahmed M, Brady S, et al. Ongoing developments in sporadic inclusion body myositis. Curr Rheumatol Rep 2014, 16:477.
19. Ware JE, Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
20. Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011, 16:191-198.
21. Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008, 37:473-476.
22. Sinclair CDJ, Morrow JM, Hanna MG, et al. Correcting radiofrequency inhomogeneity effects in skeletal muscle magnetisation transfer maps. NMR Biomed 2012, 25:262-270.
23. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. NeuroImage 2006, 31:1116-1128.
24. Reilly MM, de Jonghe P, Pareyson D 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A) 8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006, 16:396-402.
25. Lewis RA, McDermott MP, Herrmann DN, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013, 70:981-987.
26. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009, 8:1103-1110.
27. Lehr R Sixteen S-squared over D-squared: a relation for crude sample size estimates. Stat Med 1992, 11:1099-1102.
28. Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord 2013, 23:404-412.
29. Huang Y, Majumdar S, Genant HK, et al. Quantitative MR relaxometry study of muscle composition and function in Duchenne muscular dystrophy. J Magn Reson Imaging 1994, 4:59-64.
30. Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology 2010, 255:899-908.
31. Maughan RJ, Watson JS, Weir J Strength and cross-sectional area of human skeletal muscle. J Physiol 1983, 338:37-49.
32. Tollbäck A, Söderlund V, Jakobsson F, Fransson A, Borg K, Borg J Magnetic resonance imaging of lower extremity muscles and isokinetic strength in foot dorsiflexors in patients with prior polio. Scand J Rehabil Med 1996, 28:115-123.
33. Solari A, Laurà M, Salsano E, Radice D, Pareyson D Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. Neuromuscul Disord 2008, 18:19-26.
34. Carlier PG Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: different methodology, different information and different implications. Neuromuscul Disord 2014, 24:390-392.
35. Jurkat-Rott K, Weber M-A, Fauler M, et al. K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci USA 2009, 106:4036-4041.
36. Fischmann A, Morrow JM, Sinclair CDJ, et al. Improved anatomical reproducibility in quantitative lower-limb muscle MRI. J Magn Reson Imaging 2014, 39:1033-1038.
37. Hollingsworth KG, de Sousa PL, Straub V, Carlier PG Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1-2 October 2009, Paris, France. Neuromuscul Disord 2012, 22(suppl 2):S54-S67.
38. Agley CC, Rowlerson AM, Velloso CP, Lazarus NR, Harridge SDR Human skeletal muscle fibroblasts, but not myogenic cells, readily undergo adipogenic differentiation. J Cell Sci 2013, 126:5610-5625.
39. Gaeta M, Mileto A, Mazzeo A, et al. MRI findings, patterns of disease distribution, and muscle fat fraction calculation in five patients with Charcot-Marie-Tooth type 2 F disease. Skeletal Radiol 2012, 41:515-524.
40. Berciano J, Gallardo E, García A, Ramón C, Infante J, Combarros O Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family. J Neurol 2010, 257:1633-1641.
41. Pelayo-Negro AL, Gallardo E, García A, Sánchez-Juan P, Infante J, Berciano J Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study. J Neurol 2014, 261:675-685.
42. Kan HE, Scheenen TWJ, Wohlgemuth M, et al. Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2009, 19:357-362.
43. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 2004, 43:603-608.
44. McDaniel JD, Ulmer JL, Prost RW, et al. Magnetization transfer imaging of skeletal muscle in autosomal recessive limb girdle muscular dystrophy. J Comput Assist Tomogr 1999, 23:609-614.
45. Arpan I, Willcocks RJ, Forbes SC, et al. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 2014, 83:974-980.
46. Kim HK, Laor T, Horn PS, Wong B Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol 2010, 11:304-311.